Sign up Australia
Proactive Investors - Run By Investors For Investors
EPIC: ZLD
Market: ASX:ZLD
OTCBB:ZLDAF
52-week High/Low: A$0.16 / A$0.07
Sector: Pharma & Biotech
Market Cap: A$53.63M
Zelda Therapeutics Ltd (ASX:ZLD)

Zelda Therapeutics Ltd

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) is focused on the medical cannabis sector.

Zelda Therapeutics Ltd

www.zeldatherapeutics.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Zelda Therapeutics Ltd


Zelda Therapeutics Ltd Snapshot

Zelda Therapeutics has been formed to bring together some of the world's leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.

Pre-clinical

breast cancer
brain cancer
pancreatic cancer


Clinical trials

insomnia
autism
eczema

 

Last updated 16th July 2018

Dr Richard Hopkins
Managing Director

Richard is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel cancer therapies and has strong experience with corporate strategy, business development and intellectual property matters.During his career, Dr. Hopkins has managed and overseen several strategic alliance and licensing deals with multiple global pharmaceutical partners.

Most recently, he was the Chief Executive Officer of PharmAust Ltd, an ASX-listed biotechnology company.  Prior to that, he was Managing Director at Phylogica Ltd, a company he co-founded in 2001 where he also held a variety of other positions including Chief Scientific Officer and Chief Operating Officer.

Richard holds a PhD in Molecular Biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications. Dr. Hopkins currently serves as Chair of the Western Australian Ausbiotech Committee.


Harry Karelis
Founder and Executive Chairman

Harry graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States. He has in excess of 23 years diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing and has acted as a Director on several public and private companies in Australia, Singapore and the United Kingdom. Harry resides in Australia.


Mara Gordon
Founder and Director

Mara Gordon – Founder, Aunt Zelda's, Calla Spring Wellness, and Zelda Therapeutics. Mara specializes in the development of treatment protocols utilizing Bio Pharmaceutical grade cannabis extracts for seriously ill patients in California. She co-founded  Aunt Zelda's, Calla Spring Wellness, and Zelda Therapeutics in order to provide real outcomes for patients with serious diseases.  Prior to Aunt Zelda's, Mara worked as a process engineer, helping Fortune 500 companies create intelligent software by utilizing the Rational Unified Process. This experience has enabled her to take a detailed and scientific approach to utilizing cannabis as a Biopharmaceutical-grade treatment.  Gordon sits on the boards of Zelda Therapeutics, Daya Foundation, International Cannabis Standards Board (ICSB), and Hmbldt. She has presented at multiple CME-accredited medical conferences, including Patients Out of Time 2014, 2016, delivered 3.5 hour courses along with Drs. Cristina Sanchez, Manuel Guzman, Donald Abrams, and Joe D. Goldstrich. Gordon has spoken at medical cannabis conferences in Australia, Costa Rica, Chile, Colombia, the Czech Republic, Israel, as well as numerous events throughout the USA and worldwide. These include CannMed held at Harvard Medical School in April 2016, CannaTech in Israel, and Medical Marijuana for Professionals 2014 and 2016 in CO. Her work is featured in the upcoming documentaries, “Weed the People”, “Mary Janes: Women of Weed”, and in Joe Dolce’s book, “Brave New Weed”. Mara resides in California.


Jason Peterson
Founder and Director

Jason is a Director, major shareholder and Head of Corporate of boutique stock broking and corporate advisory firm, CPS Capital. He has more than 19 years experience in the financial advisory sector, which he obtained by working in both local and international stockbroking companies such as Patersons, Tolhurst, and Merrill Lynch. He specialises in corporate structuring, capital raisings, corporate and strategic advice to small and medium size companies and reverse takeovers. He holds a Bachelor of Commerce degree from Curtin University and a Graduate Diploma of Finance from FINSIA (Financial Services Institute of Australia)/SDIA (Securities & Derivatives Institute of Australia). Jason resides in Australia.


Dr Stewart Washer
Founder and Director

Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently Chairman of ASX-listed Orthocell Ltd (culturing tendon cells to repair damaged tendons) and Cynata Therapeutics Ltd (developing stem cell therapies) and Chairman of privately-held Minomic International Ltd (accurate non-invasive test for prostate cancer). Stewart has held several past senior executive roles including CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. Stewart resides in Australia.

 

Last updated 16th July 2018

Level 26, 140 St Georges Terrace
Perth WA 6000

Telephone: (08) 6558 0886
Fax: (08) 6316 3337
Email: [email protected]
Website: www.zeldatherapeutics.com

Zelda Therapeutics Ltd Timeline

Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use